Philip Mease
- Rheumatology top 1%
- Spondyloarthritis Studies and Treatments 12
- Rheumatoid Arthritis Research and Therapies 8
- Hematology top 2%
- Autoimmune and Inflammatory Disorders Research 6
- Immunology top 2%
- Psoriasis: Treatment and Pathogenesis 12
- Biosimilars and Bioanalytical Methods 2
- Dermatology top 2%
- Complementary and Manual Therapy top 10%
-
- Fibromyalgia and Chronic Fatigue Syndrome Research 3
-
- Health Systems, Economic Evaluations, Quality of Life 3
-
- Pharmaceutical studies and practices 3
- Co-authors
- Peter NashDafna D. GladmanDaniel O. CleggChristian AntoniLesley M. ArnoldStuart SilvermanShephard MpofuIain B. McInnes
- Cited by
- RheumatologyHematologyImmunology
- Journals
- Annals of the Rheumatic Diseases (2 papers)Journal of the American Academy of Dermatology (2 papers)Psychosomatic Medicine (1 paper)
- Partner nations
- United StatesUnited KingdomGermany
In The Last Decade
Philip Mease
21 papers receiving 1.3k citations
Hit Papers
Peers
Comparison fields: 5 of 74
- Rheumatology 974
- Hematology 558
- Immunology 983
- Dermatology 188
- Complementary and Manual Therapy 16
Countries citing papers authored by Philip Mease
This map shows the geographic impact of Philip Mease's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philip Mease with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philip Mease more than expected).
Fields of papers citing papers by Philip Mease
This network shows the impact of papers produced by Philip Mease. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philip Mease. The network helps show where Philip Mease may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Philip Mease, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2022 | 6 | |
| 2 | 2021 | 2 | |
| 3 | Residual Disease Activity in Psoriatic Arthritis Patients Treated with Secukinumab and Adalimumab Who Achieved Remission or Low Disease Activity: Results from a Phase 3b, Randomized, Double-blinded, Active-controlled, Head-to-head Study | 2020 | 1 |
| 4 | 2020 | 1 | |
| 5 | 2020 | 2 | |
| 6 | Phase 2 Study of ABT-122, a TNF- and IL-17A-Targeted Dual Variable Domain Immunoglobulin, in Psoriatic Arthritis With Inadequate Methotrexate Response. | 2018 | 6 |
| 7 | 2018 | 1 | |
| 8 | Secukinumab Safety and Tolerability in Patients with Active Psoriatic Arthritis and Psoriasis: Results From a Pooled Safety Analysis | 2016 | 2 |
| 9 | 2015 | 17 | |
| 10 | Long-Term Safety and Efficacy of Certolizumab Pegol over 96 Weeks in Patients with Psoriatic Arthritis with and without Prior Tumor Necrosis Factor Inhibitor Exposure | 2014 | 1 |
| 11 | Secukinumab, a Human Anti-Interleukin-17A Monoclonal Antibody, Improves Active Psoriatic Arthritis and Inhibits Radiographic Progression: Efficacy and Safety Data from a Phase 3 Randomized, Multicenter, Double-Blind, Placebo-Controlled Study | 2014 | 12 |
| 12 | Secukinumab, a Human Anti-Interleukin-17A Monoclonal Antibody, Significantly Reduces Psoriasis Burden in Patients with Psoriatic Arthritis: Results from a Phase 3 Randomized Controlled Trial | 2014 | 12 |
| 13 | EFFECT OF CERTOLIZUMAB PEGOL ON SIGNS AND SYMPTOMS IN PATIENTS WITH PSORIATIC ARTHRITIS WITH OR WITHOUT PRIOR ANTI-TNF EXPOSURE : 24-WEEK RESULTS OF A PHASE III DOUBLE-BLIND RANDOMIZED PLACEBO-CONTROLLED STUDY | 2013 | 4 |
| 14 | 2013 | 5 | |
| 15 | 2012 | 20 | |
| 16 | Pregabalin: an alpha2-delta (alpha2-delta) ligand for the management of fibromyalgia. | 2010 | 20 |
| 17 | 2008 | 3 | |
| 18 | 2006 | 6 | |
| 19 | Psoriatic arthritis: epidemiology, clinical features, course, and outcomebreakdown → | 2005 | 1176 |
| 20 | 2004 | 4 |
About Philip Mease
Philip Mease is a scholar working on Rheumatology, Immunology and Hematology, having authored 21 papers that have together received 1.3k indexed citations. Recurring topics across this work include Psoriasis: Treatment and Pathogenesis (12 papers), Spondyloarthritis Studies and Treatments (12 papers), Rheumatoid Arthritis Research and Therapies (8 papers), Autoimmune and Inflammatory Disorders Research (6 papers), Fibromyalgia and Chronic Fatigue Syndrome Research (3 papers), Health Systems, Economic Evaluations, Quality of Life (3 papers), Pharmaceutical studies and practices (3 papers) and Biosimilars and Bioanalytical Methods (2 papers). The work is most often cited by research in Rheumatology (974 citations), Hematology (558 citations) and Immunology (983 citations). Philip Mease has collaborated with scholars based in United States, United Kingdom and Germany. Frequent co-authors include Peter Nash, Dafna D. Gladman, Daniel O. Clegg, Christian Antoni, Lesley M. Arnold, Stuart Silverman, Shephard Mpofu, Iain B. McInnes, Arthur Kavanaugh and Fujun Wang. Their work appears in journals such as Annals of the Rheumatic Diseases, Journal of the American Academy of Dermatology and Psychosomatic Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.